10-Q: STAAR Surgical Reports Q3 Growth Amid Alcon Merger Battle

STAAR Surgical Company reported increased net sales and gross profit for Q3 2025, driven by China sales and cost reductions, while facing a significant year-to-date net loss and a proxy contest over its proposed $28.00 per share acquisition by Alcon.

Summary

• Net sales for the three months ended September 26, 2025, increased by 6.9% to $94.7 million compared to $88.6 million in the prior year period.
• Gross profit for Q3 2025 rose by 13.7% to $77.9 million, with gross margin improving to 82.2% from 77.3% in Q3 2024, primarily due to the recognition of the December China Shipment at 100% gross margin.
• The company reported a net income of $8.9 million ($0.18 per diluted share) for Q3 2025, a decrease from $10.0 million ($0.20 per diluted share) in Q3 2024.
• For the nine months ended September 26, 2025, net sales decreased significantly by 31.4% to $181.6 million from $265.0 million in the prior year, primarily due to decreased China sales.
• A net loss of $62.1 million ($-1.26 per diluted share) was recorded for the nine months ended September 26, 2025, compared to a net income of $14.0 million ($0.28 per diluted share) for the same period in 2024.
• The company incurred $5.9 million in merger transaction and related costs during Q3 2025 and $27.9 million in restructuring, impairment, and related charges for the nine months ended September 26, 2025.
• A proposed merger with Alcon Research, LLC for $28.00 per share in cash is pending, with the Special Meeting for stockholder adoption postponed to December 3, 2025.
• Broadwood Partners, L.P., a significant shareholder (27.4%), is actively soliciting votes against the merger and intends to request a separate special meeting to remove several directors.
• Cash and cash equivalents increased to $176.2 million as of September 26, 2025, from $144.2 million at December 27, 2024, while investments available for sale decreased from $86.3 million to $16.5 million.
• A share repurchase program authorized in May 2025 for up to $30 million has seen $6.5 million in repurchases year-to-date, with $23.5 million remaining available.
• The company implemented consignment agreements with its China distributors in April 2025 to mitigate tariff exposure and is ramping up production capabilities in Switzerland.
• Restructuring efforts, including leadership realignment and workforce reduction, were substantially completed as of June 27, 2025, incurring $12.5 million in severance costs and $14.6 million in asset impairments.

Sentiment

Score: 4

Explanation: The sentiment is mixed to negative. While Q3 showed some recovery in sales and gross margin, the year-to-date performance is significantly negative with a substantial net loss and decline in sales. The ongoing merger with Alcon offers a fixed exit price, but the strong shareholder opposition and associated risks introduce considerable uncertainty. The underlying operational performance, excluding merger-related factors, appears challenged, despite cost reduction efforts.

Positives

• Net sales for the three months ended September 26, 2025, increased by 6.9% to $94.7 million, showing a positive quarterly trend.
• Gross profit margin improved significantly to 82.2% in Q3 2025 from 77.3% in Q3 2024, partly due to the recognition of the December China Shipment at 100% gross margin.
• Operating income for Q3 2025 increased substantially to $18.5 million from $5.7 million in Q3 2024.
• General and administrative expenses decreased by 4.3% in Q3 2025 and 3.4% year-to-date, reflecting cost reduction efforts.
• Selling and marketing expenses decreased by 18.7% in Q3 2025 and 13.4% year-to-date, indicating reduced discretionary spending.
• Research and development expenses decreased by 24.8% in Q3 2025 and 13.3% year-to-date, partly due to lower clinical expenses and in-process R&D purchases.
• Cash and cash equivalents increased by $32.0 million to $176.2 million, enhancing liquidity.
• The company is actively mitigating tariff risks in China by implementing consignment agreements and increasing production capacity in Switzerland.
• The restructuring effort was substantially completed as of June 27, 2025, suggesting that the significant one-time charges are largely behind the company.

Negatives

• Net sales for the nine months ended September 26, 2025, decreased significantly by 31.4% to $181.6 million, primarily due to reduced China sales.
• The company reported a substantial net loss of $62.1 million for the nine months ended September 26, 2025, compared to a net income of $14.0 million in the prior year period.
• Gross profit for the nine months ended September 26, 2025, decreased by 33.3% to $138.7 million, and gross margin declined to 76.3% from 78.5% year-to-date, attributed to higher manufacturing costs per unit and increased inventory reserves.
• Operating income shifted to a significant loss of $68.9 million for the nine months ended September 26, 2025, from an income of $15.3 million in the prior year.
• The accumulated deficit increased to $129.7 million as of September 26, 2025, from $67.6 million at December 27, 2024, reflecting the year-to-date net loss.
• Net cash used in operating activities was $30.3 million for the nine months ended September 26, 2025, a reversal from $15.1 million provided in the prior year.
• The company incurred $5.9 million in merger transaction costs and $27.9 million in restructuring, impairment, and related charges year-to-date, impacting profitability.
• Investments available for sale decreased significantly by $69.8 million, indicating a shift in investment strategy or liquidity needs.

Risks

• The proposed acquisition by Alcon could adversely impact business, financial condition, and results of operations due to uncertainty among employees, customers, and other parties.
• Difficulty in attracting, retaining, and motivating employees, including key personnel, due to merger uncertainty.
• Diversion of significant management time and resources towards completing the merger and responding to related stockholder activism.
• Challenges in maintaining relationships with customers, suppliers, and other business partners.
• Delays or deferments of certain business decisions by customers, suppliers, and other business partners.
• Inability to pursue alternative business opportunities or make appropriate changes to the business due to merger agreement covenants.
• Litigation relating to the merger and associated costs.
• Incurrence of significant costs, expenses, and fees for professional services and other transaction costs in connection with the merger and stockholder activism.
• Failure to consummate the merger due to unfulfilled closing conditions, including stockholder approval and regulatory conditions, could adversely impact the business.
• The Broadwood Group, holding approximately 27.4% of outstanding shares, intends to vote against the merger and has initiated a proxy contest to remove several directors, potentially jeopardizing stockholder approval.
• The merger is subject to antitrust approvals in China and Japan, which may not be granted or may impose burdensome conditions.
• A material adverse effect on the company since the merger agreement date could allow Alcon to terminate the agreement.
• Potential termination fees: the company may pay Alcon up to $43.4 million, or Alcon may pay the company $72.4 million under specified circumstances.
• A failed merger could result in negative publicity, a negative impression among stakeholders, and a decline in share price if the current market price reflects an assumption of merger completion.
• Ongoing legal proceedings and other matters arising in the normal course of business, including contractual rights, employment, product liability, or merger-related claims, could lead to significant financial harm.

Future Outlook

The company expects to continue incurring professional service expenses until the proposed merger with Alcon is finalized. It anticipates that purchases by China distributors will largely be satisfied from consigned inventory in-country in the near-term, leading to more frequent, smaller purchases aligned with actual procedural volumes. This strategy aims to reduce the risk of elevated distributor inventory buildup while maintaining sufficient ICL inventory. The company is also rapidly ramping up production capabilities in Switzerland to supplement U.S. manufacturing capacity, providing optionality under multiple tariff scenarios. The company believes its current liquidity sources will be sufficient for at least 12 months, but future capital requirements will depend on growth rate, spending to support strategy, new product introductions, and macroeconomic factors.

Management Comments

• The Board of Directors has unanimously determined that the Merger Agreement and the transactions contemplated thereby are fair to, and in the best interests of, the Company and its stockholders.
• The Board of Directors has approved and declared advisable the Merger Agreement and the transactions contemplated thereby.
• The Board of Directors has resolved to recommend that the Company's stockholders adopt the Merger Agreement.
• We believe that these efforts to increase the amount of ICLs in China reduce the Company's tariff risk in China in the near-term.
• We are rapidly ramping up our production capabilities in Switzerland to supplement our manufacturing capacity in the United States to provide optionality under multiple tariff scenarios.
• We believe that purchases by our distributors will largely be satisfied from our consigned inventory in-country in the near-term, rather than through bulk purchases.
• We believe this will reduce the risk of elevated inventory buildup by our distributors, while at the same time maintaining sufficient ICL inventory in China to support quick and efficient delivery and fulfillment for surgical procedures.
• We believe these sources of liquidity will be sufficient to meet our anticipated cash needs, including working capital needs, capital expenditures and contractual obligations for at least 12 months from the issuance date of the financial statements.

Industry Context

The ophthalmic surgical product industry, particularly for implantable lenses, is influenced by global macroeconomic conditions, trade policies, and technological advancements. STAAR Surgical's focus on ICLs positions it in the premium refractive surgery segment. The significant decrease in year-to-date China sales highlights the sensitivity of the market to regional economic dynamics and inventory management practices. The company's strategic shift to consignment sales in China and diversification of manufacturing to Switzerland are direct responses to evolving trade tariffs and supply chain risks, reflecting a broader industry trend towards supply chain resilience. The proposed acquisition by Alcon, a major player in eye care, indicates consolidation within the industry and Alcon's interest in expanding its premium refractive offerings, potentially intensifying competition for other independent ICL manufacturers or alternative refractive solutions.

Comparison to Industry Standards

• NA

Management Changes

Corporate Governance

Legal Proceedings

• The company is involved in various legal proceedings and other matters arising in the normal course of business, including contractual rights and obligations, employment matters, claims of product liability, or claims relating to the Merger and related disclosures.
• Litigation relating to the Merger has been filed, and additional litigation may be filed against the company or its directors or officers, potentially seeking damages and/or to enjoin the Merger.

Stakeholder Impact

• Shareholders: Directly impacted by the proposed merger price of $28.00 per share, the outcome of the stockholder vote, and the ongoing proxy contest by Broadwood Group, which could influence the company's future direction and share price.
• Employees: Risk of impairment to the company's ability to attract, retain, and motivate employees, including key personnel, due to uncertainty surrounding the merger.
• Customers and Suppliers: Potential difficulties in maintaining relationships and delays or deferments of business decisions due to the merger's pendency.
• Management: Significant diversion of time and resources towards completing the merger and responding to stockholder activism, potentially impacting operational focus.
• Creditors: The company's financial health and ability to meet obligations could be affected by the merger's outcome, particularly if termination fees are incurred or if the business is adversely impacted by a failed transaction.

Next Steps

• Stockholders will vote on the adoption of the Merger Agreement at a special meeting on December 3, 2025.
• The company expects to continue to incur professional service expenses until the Merger with Alcon is finalized.
• The company will adopt the annual disclosure requirements of ASU 2024-03 at the beginning of fiscal year 2026 and interim disclosure requirements beginning fiscal year 2027.
• The company continues to evaluate the impact of the One Big Beautiful Bill Act (OBBBA) on its Condensed Consolidated Financial Statements.

Key Dates

Recommendation

The stock is currently subject to a proposed cash acquisition by Alcon at $28.00 per share. While the year-to-date financial performance shows significant challenges, the merger offers a clear exit price. However, the strong opposition from a major shareholder (Broadwood Group) introduces substantial uncertainty regarding the merger's completion. Investors should hold to see the outcome of the December 3, 2025, stockholder vote, as a failure of the merger could lead to a significant decline in share price given the underlying operational losses, while successful completion would realize the $28.00 per share value. The current situation is dominated by the merger arbitrage opportunity and its associated risks rather than the company's standalone operational performance.

Keywords

STAAR Surgical, Alcon Merger, 10-Q, Q3 2025 Earnings, Implantable Collamer Lenses, ICL, Ophthalmic Surgery, Financial Results, SEC Filing, Shareholder Activism, Broadwood Group, China Sales, Tariffs, Restructuring, Medical Devices, Refractive Surgery